These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31863494)

  • 1. Epigenetic control of tumor angiogenesis.
    Ribatti D; Tamma R
    Microcirculation; 2020 Apr; 27(3):e12602. PubMed ID: 31863494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual targeting of epigenetic therapy in cancer.
    Hellebrekers DM; Griffioen AW; van Engeland M
    Biochim Biophys Acta; 2007 Jan; 1775(1):76-91. PubMed ID: 16930846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.
    Berndsen RH; Abdul UK; Weiss A; Zoetemelk M; Te Winkel MT; Dyson PJ; Griffioen AW; Nowak-Sliwinska P
    Angiogenesis; 2017 May; 20(2):245-267. PubMed ID: 28378227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of epigenetically silenced genes in tumor endothelial cells.
    Hellebrekers DM; Melotte V; Viré E; Langenkamp E; Molema G; Fuks F; Herman JG; Van Criekinge W; Griffioen AW; van Engeland M
    Cancer Res; 2007 May; 67(9):4138-48. PubMed ID: 17483324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells.
    Khan MA; Hussain A; Sundaram MK; Alalami U; Gunasekera D; Ramesh L; Hamza A; Quraishi U
    Oncol Rep; 2015 Apr; 33(4):1976-84. PubMed ID: 25682960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy.
    Gkotzamanidou M; Terpou E; Kentepozidis N; Terpos E
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapeutic targets in cancer: the epigenetic connection.
    Herranz M; Esteller M
    Clin Transl Oncol; 2006 Apr; 8(4):242-9. PubMed ID: 16648099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human DNA (cytosine-5)-methyltransferases: a functional and structural perspective for epigenetic cancer therapy.
    Rondelet G; Wouters J
    Biochimie; 2017 Aug; 139():137-147. PubMed ID: 28600135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mechanism and potential targets of class II HDACs in angiogenesis.
    Hou F; Li D; Yu H; Kong Q
    J Cell Biochem; 2018 Apr; 119(4):2999-3006. PubMed ID: 29091298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors.
    Katarzyna R; Lucyna B
    J Cancer Res Ther; 2019; 15(5):961-970. PubMed ID: 31603095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylases and cancer-associated angiogenesis: current understanding of the biology and clinical perspectives.
    Turtoi A; Peixoto P; Castronovo V; Bellahcène A
    Crit Rev Oncog; 2015; 20(1-2):119-37. PubMed ID: 25746107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications.
    Hellebrekers DM; Castermans K; Viré E; Dings RP; Hoebers NT; Mayo KH; Oude Egbrink MG; Molema G; Fuks F; van Engeland M; Griffioen AW
    Cancer Res; 2006 Nov; 66(22):10770-7. PubMed ID: 17108113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of novel epigenetic molecular-targeting agents].
    Sowa Y; Sakai T
    Nihon Rinsho; 2015 Aug; 73(8):1263-7. PubMed ID: 26281676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavonoids as Epigenetic Modulators for Prostate Cancer Prevention.
    Izzo S; Naponelli V; Bettuzzi S
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32268584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research Progress of Epigenetics in Pathogenesis and Treatment of Malignant Tumors].
    Wang P; Zhao H; Ren F; Zhao Q; Shi R; Liu X; Liu J; Li Y; Li Y; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2020 Feb; 23(2):91-100. PubMed ID: 32093453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells.
    Lee SH; Kim J; Kim WH; Lee YM
    Oncogene; 2009 Jan; 28(2):184-94. PubMed ID: 18850007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer.
    Oh S; Ko JY; Oh C; Yoo KH
    Adv Exp Med Biol; 2017; 1026():287-313. PubMed ID: 29282690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
    Valdespino-Gómez VM; Valdespino-Castillo VE
    Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.